Improving Headache Management in the Pediatric Emergency Department
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
In this medfyle
Expert commentary by Amy A. Gelfand, MD, MAS, FAHS
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:
Jessica L. Hauser, MD, PhD
Resident Physician, Child Neurology PGY4
University of Washington, Seattle Children’s Hospital
Seattle, Washington
The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Amy A. Gelfand, MD, MAS, FAHS
University of California San Francisco
About the Expert
Amy A. Gelfand, MD, MAS, FAHS
University of California San Francisco
Dr. Amy Gelfand is an Associate Professor of Neurology & Pediatrics at the University of California, San Francisco. She directs the Child & Adolescent Headache Program at the UCSF Benioff Childrens’ Hospitals. Her research interests include examining the role of melatonin in the treatment of pediatric migraine, and the relationship between infant colic and migraine.
References
1. Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics 2015;135:232-238.
2. Patniyot, I.R. and Gelfand, A.A. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache: The Journal of Head and Face Pain 2016;56:49-70.
3. Goadsby, P., Zanchin, G., Geraud, et al. Early vs. Non-Early Intervention in Acute Migraine — ‘Act When Mild (AwM)’. A Double-Blind, Placebo-Controlled Trial of Almotriptan. Cephalalgia 2008; 28: 383–391.
